Paper36979640
Recoding of Nonsense Mutation as a Pharmacological Strategy.
Temaj G and 5 others. Biomedicines, 2023. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Recoding of Nonsense Mutation as a Pharmacological Strategy. Papers, record 36979640. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36979640
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References166
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22938201 | Rescue of nonsense mutations by amlexanox in human cells. | Orphanet J Rare Dis | 2012 | https://conductscience.org/library/papers/22938201 | PubMed |
| 2 | 1569946 | Gene products that promote mRNA turnover in Saccharomyces cerevisiae. | Mol Cell Biol | 1992 | https://conductscience.org/library/papers/1569946 | PubMed |
| 3 | 3060001 | Genetics of Streptomyces fradiae and tylosin biosynthesis. | Annu Rev Microbiol | 1988 | https://conductscience.org/library/papers/3060001 | PubMed |
| 4 | 15125646 | Enhanced production of functional proteins from defective genes. | J Am Chem Soc | 2004 | https://conductscience.org/library/papers/15125646 | PubMed |
| 5 | 29334995 | Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations. | Genome Biol | 2018 | https://conductscience.org/library/papers/29334995 | PubMed |
| 6 | 23774824 | A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. | Mol Ther | 2013 | https://conductscience.org/library/papers/23774824 | PubMed |
| 7 | 12718880 | Y14 and hUpf3b form an NMD-activating complex. | Mol Cell | 2003 | https://conductscience.org/library/papers/12718880 | PubMed |
| 8 | 17664317 | Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17664317 | PubMed |
| 9 | 33764477 | Effect of small molecule eRF3 degraders on premature termination codon readthrough. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33764477 | PubMed |
| 10 | 30650260 | Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers. | Clin Pharmacol Drug Dev | 2019 | https://conductscience.org/library/papers/30650260 | PubMed |
| 11 | 21596314 | Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. | Mol Cell | 2011 | https://conductscience.org/library/papers/21596314 | PubMed |
| 12 | 26787741 | Nonsense-mediated mRNA decay in humans at a glance. | J Cell Sci | 2016 | https://conductscience.org/library/papers/26787741 | PubMed |
| 13 | 28145797 | Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. | RNA Biol | 2017 | https://conductscience.org/library/papers/28145797 | PubMed |
| 14 | 34272367 | A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. | Nat Commun | 2021 | https://conductscience.org/library/papers/34272367 | PubMed |
| 15 | 28096517 | The nucleoside analog clitocine is a potent and efficacious readthrough agent. | RNA | 2017 | https://conductscience.org/library/papers/28096517 | PubMed |
| 16 | 27784737 | Readthrough-Promoting Drugs Gentamicin and PTC124 Fail to Rescue Nav1.5 Function of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Carrying Nonsense Mutations in the Sodium Channel Gene SCN5A. | Circ Arrhythm Electrophysiol | 2016 | https://conductscience.org/library/papers/27784737 | PubMed |
| 17 | 34769402 | Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34769402 | PubMed |
| 18 | 19417105 | Structural insights into eRF3 and stop codon recognition by eRF1. | Genes Dev | 2009 | https://conductscience.org/library/papers/19417105 | PubMed |
| 19 | 32435380 | Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs). | ACS Med Chem Lett | 2020 | https://conductscience.org/library/papers/32435380 | PubMed |
| 20 | 33391025 | A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay. | Front Physiol | 2020 | https://conductscience.org/library/papers/33391025 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42123532 | Neuromuscular Disorders in Children Through the Lens of Next-Generation Sequencing: A Study of Diagnostic Yield. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123532 | PubMed |
| 41986644 | Rescuing TP53 from nonsense: novel triazoles for translational readthrough via optimized drug design. | Sci Rep | 2026 | https://conductscience.org/library/papers/41986644 | PubMed |
| 41939791 | Identification of small molecules that enhance aminoglycoside-mediated suppression of CFTR and NF1 nonsense mutations. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41939791 | PubMed |
| 41015699 | Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutations. | J Cyst Fibros | 2026 | https://conductscience.org/library/papers/41015699 | PubMed |
| 40420818 | Advancing Therapeutic Strategies for Nonsense-Related Diseases: From Small Molecules to Nucleic Acid-Based Innovations. | IUBMB Life | 2025 | https://conductscience.org/library/papers/40420818 | PubMed |
| 40156864 | Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40156864 | PubMed |
| 39582793 | Systematic deletion of symmetrical CFTR exons reveals new therapeutic targets for exon skipping antisense oligonucleotides. | NAR Mol Med | 2024 | https://conductscience.org/library/papers/39582793 | PubMed |
| 39395187 | StopKB: a comprehensive knowledgebase for nonsense suppression therapies. | Database (Oxford) | 2024 | https://conductscience.org/library/papers/39395187 | PubMed |
Genes44
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36979640
GET https://conductscience.org/api/papers/v1/36979640/references?page=2